Data from Pharmawand - Curated by EPG Health - Date added 10 November 2019
Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd, Celltrion, Inc., and Celltrion Healthcare, Co., Ltd.announced that Truxima (rituximab-abbs) injection is the first biosimilar to the reference product Rituxan (rituximab) now available in the United States with a full oncology label. Truxima is currently indicated for the treatment of adult patients with non-Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL).
Truxima was approved by the FDA as the first rituximab biosimilar. The approval was based on a review of a comprehensive data package inclusive of foundational and extensive analytical characterization, nonclinical data, clinical pharmacology, immunogenicity, clinical efficacy, and safety data. In May 2019, the FDA approved Truxima to match all of the reference product’s oncology indications for NHL and CLL.
In light of a patent settlement with Genentech, Celltrion and Teva have a pending FDA submission for rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA), and microscopic polyangiitis (MPA), and a license from Genentech to expand the Truxima label to include these indications in Q2 2020.The Wholesale Acquisition Cost (WAC or “list price”) for Truxima will be 10 percent lower than the reference product.
Learning Zones
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
Chronic Lymphocytic Leukaemia (CLL)
Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more
+ 1 more
Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive fibrotic interstitial lung disease that occurs mostly in older adults, is limited to the lungs and often displays a characteristic imaging and histological appearance. Find out how to diagnose IPF and the latest interventions available for patients living with this burden.
Oral Anticoagulation Reversal
Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients.
Comments
You will need to login, to leave a comment.
epgonline.org is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.